Stifel analyst Jonathan Block lowered the firm’s price target on Nyxoah (NYXH) to $11 from $12 and keeps a Buy rating on the shares as part of the firm’s Animal Health, Sleep, and Vision overview for 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NYXH:
- Nyxoah Expands Belgian Manufacturing Hub to Support Global Sleep Apnea Growth
- Nyxoah to invest in manufacturing facility in Belgium
- Nyxoah’s First Full U.S. Sales Quarter Fuels Triple-Digit Revenue Growth in 2025
- Nyxoah sees Q1 net revenue up 25% over Q1
- Nyxoah reports preliminary Q4 gross revenue EUR 6.3M